Gallant | Regenerative Medicine for Pets
What Makes Gallant Different?
Regenerative medicine that goes deeper
Most therapies just manage symptoms. Gallant’s stem cell therapies for pets are designed to help restore health at the source by:
- reducing inflammation
- restoring tissue function
- supporting long-term recovery
Our Therapies in Development
Every therapy in our pipeline follows the FDA’s structured review and approval process—ensuring quality, consistency, and a path to better care for pets and the people who love and care for them.
| Pre-clinical | proof of concept |
Controlled field study | Pivotal study | Commercially available | |
|---|---|---|---|---|---|
| Feline Chronic Gingivostomatitis | |||||
| Feline Osteoarthritis | |||||
| Canine Osteoarthritis | |||||
| Feline Chronic Kidney Disease | |||||
| Canine Atopic Dermatitis |
Explore our Clinical Trials
Be a pet health hero
We’re working with veterinarians and pet families across the U.S. to bring regenerative therapies to pets who need them most.
See what studies are enrolling—and how you can get involved.
You & Gallant
Advancing veterinary medicine – together
Gallant’s investigational stem cell therapies are designed for real-world practice—ready-to-use, easy to administer, and backed by science. Let’s make regenerative medicine simple to deliver and impactful where it matters most.
Making Headlines in Animal Health
Gallant is being recognized for advancing regenerative medicine with rigor, transparency, and real-world impact.
LA Times highlights Gallant’s stem cell study for feline chronic gingivostomatitis
Read more
Dr. Rebecca Windsor on stem cell therapy advances in FCGS
Read more
dvm360: busting myths around stem cell therapy
Read more
TechCrunch spotlights Gallant’s breakthrough approach to pet stem cell therapy
Read more
Veterinary Advantage Q&A With Dr. Linda Black DVM, PhD: restoring health at the source
Read more
BioProcess Insider covers Gallant’s $18M raise and manufacturing expansion
Read more
The Latest from Gallant
Gallant Advances Canine Osteoarthritis IV-Delivered Stem Cell Therapy with Promising Pilot Data and Expanded FDA Conditional Approval Pathway Eligibility
Read more
Gallant Reports Positive Pilot Data for Feline Osteoarthritis Stem Cell Therapy; Receives FDA Eligibility for Expanded Conditional Approval Pathway
Read more
National Survey: Veterinary Professionals See Stem Cell Therapy as a Powerful New Tool for Inflammatory Diseases in Pets
Read more
Work With Us
Where science meets mission
Gallant is redefining what’s possible in pet health—and it takes passionate people from every discipline to make it happen. If you’re driven by purpose, energized by innovation, and ready to help bring regenerative medicine to more pets, let’s talk.